BRD4 and pulmonary arterial hypertension: This study was the first to identify BRD4 as a therapeutic candidate for treating PAH and suggested that targeting BRD4 with specific inhibitors could reduce PASMC proliferation and decrease pulmonary artery pressure, potentially halting or slowing the progression of PAH.